Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Company Deals

Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries

Fineline Cube Jul 4, 2024

Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has...

Company Deals

United Imaging Healthcare to Launch Financial Leasing Arm with RMB 450 Million Investment

Fineline Cube Jul 4, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical equipment company based in Shanghai, has...

Company Deals

Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda

Fineline Cube Jul 4, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC

Fineline Cube Jul 4, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Drug

HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA

Fineline Cube Jul 4, 2024

HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...

Company Medical Device

Blue Sail Medical’s Fastroad Catheter Earns NMPA Marketing Approval

Fineline Cube Jul 4, 2024

Blue Sail Medical Co., Ltd (SHE: 002382), a medical device company based in China, has...

Company

Philips Appoints Liu Ling as Greater China President Amid Leadership Changes

Fineline Cube Jul 4, 2024

Dutch multinational Philips has appointed Liu Ling as President of Greater China, effective immediately. Liu...

Company Deals

CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China

Fineline Cube Jul 4, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...

Company Deals

Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America

Fineline Cube Jul 4, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL...

Company Deals

GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership

Fineline Cube Jul 4, 2024

GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership...

Company Deals

China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions

Fineline Cube Jul 4, 2024

Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its...

Company Drug

LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China

Fineline Cube Jul 4, 2024

LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...

Company Drug

AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment

Fineline Cube Jul 4, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...

Company Deals

Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round

Fineline Cube Jul 3, 2024

Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series...

Company Drug

Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment

Fineline Cube Jul 3, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...

Posts pagination

1 … 375 376 377 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.